Publications by authors named "C Crespel"
Aims: The EXTREME regimen is the standard for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). However, many patients have a poor performance status and/or comorbidities, making them unfit for this regimen. We have treated them with carboplatin and cetuximab (simplified EXTREME regimen) since 2007.
View Article and Find Full Text PDFArticle Synopsis
- Homologous recombination deficiency may indicate how well patients with cervical cancer respond to poly(ADP-ribose) polymerase (PARP) inhibitors, a treatment option not previously explored for this type of cancer.
- A 49-year-old woman with advanced cervical cancer demonstrated a partial response after standard treatment, and genetic testing revealed a harmful BRCA1 mutation, leading to a combination treatment of olaparib and bevacizumab.
- Following two years of stable disease and a hysterectomy that showed no cancer, this case suggests PARP inhibitors like olaparib could be effective for advanced cervical cancer and highlights the need for clinical trials to investigate this further.
Patients who carry the BReast Cancer 1 or 2 (BRCA) gene mutations have an underlying hereditary predisposition for breast and ovarian cancers. These deleterious genetic mutations are the most common ones implicated in hereditary breast and ovarian cancers. Oncogenetic counselling plays a key role in identifying patient for BRCA testing and for mutation identification.
View Article and Find Full Text PDFIntroduction: Adapted physical activity (APA) is recognized as an effective supportive care for asthenia and quality of life in oncology. Before an APA program was organized, the feasibility of such a program was evaluated among the patients.
Methods: Descriptive, prospective, semi-qualitative, single-center study over a 3-month period in patients treated with ambulatory chemotherapy for digestive cancer.